Multimodal MR imaging (diffusion, perfusion, and spectroscopy): Is it possible to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis?

American Journal of Neuroradiology

Volumn 34, Issue 7, 2013, Pages 1326-1333

  Fellah, S ^a   Caudal, D ^d   De Paula, A M ^d   Dory Lautrec, P ^d   Figarella Branger, D ^b,d   Chinot, O ^d   Metellus, P ^d   Cozzone, P J ^a   Confort Gouny, S ^a   Ghattas, B ^c   Callot, V ^a   Girard, N ^d  

^a University of Aix Marseille   (France)

^b University of the Mediterranean Aix Marseille II   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d TIMONE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; ASTROCYTOMA; CANCER GRADING; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION WEIGHTED IMAGING; FEMALE; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE SCANNER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OLIGODENDROGLIOMA; PERFUSION WEIGHTED IMAGING; PREDICTIVE VALUE; RANDOM FOREST; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASTROCYTOMA; BRAIN NEOPLASMS; CEREBRAL CORTEX; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; FRONTAL LOBE; GENOTYPE; HUMANS; IMAGE ENHANCEMENT; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NEOPLASM GRADING; OLIGODENDROGLIOMA; RETROSPECTIVE STUDIES; SEQUENCE DELETION; TEMPORAL LOBE; YOUNG ADULT;

EID: 84880842572     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A3352     Document Type: Article

References (32)

1. Jenkins RB, Blair H, Ballman KV, et al. At(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006;66:9852-61.
2. Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000;18: 636-45.
3. Walker C, Haylock B, Husband D, et al. Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors. Neurology 2006;66:1661-67.
4. Sasaki H, Zlatescu MC, Betensky RA, et al. Histopathological-molecular genetic correlations in referral pathologist-diagnosed lowgrade "oligodendroglioma". J Neuropathol Exp Neurol 2002;61: 58-63.
5. Dean BL, Drayer BP, Bird CR, et al. Gliomas: classification with MR imaging. Radiology 1990;174:411-15.
6. Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003;24:1989-98.
7. Jenkinson MD, Smith TS, Joyce KA, et al. Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours. Neuroradiology 2006;48:703-13.
8. Law M, Yang S, Babb JS, et al. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrastenhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol 2004;25:746-55.
9. Stadlbauer A, Gruber S, Nimsky C, et al. Preoperative grading of gliomas by using metabolite quantification with high-spatial-resolution proton MR spectroscopic imaging. Radiology 2006;238: 958-69.
10. Jenkinson MD, Smith TS, Brodbelt AR, et al. Apparent diffusion coefficients in oligodendroglial tumors characterized by genotype. J Magn Reson Imaging 2007;26:1405-12.
11. Law M, Brodsky JE, Babb J, et al. High cerebral blood volume in human gliomas predicts deletion of chromosome 1p: preliminary results of molecular studies in gliomas with elevated perfusion. J Magn Reson Imaging 2007;25:1113-19.
12. Jenkinson MD, du Plessis DG, Smith TS, et al. Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain 2006;129:1884-91.
13. Jenkinson MD, Smith TS, Joyce K, et al. MRS of oligodendroglial tumors: correlation with histopathology and genetic subtypes. Neurology 2005;64:2085-89.
14. Kapoor GS, Gocke TA, Chawla S, et al. Magnetic resonance perfusion- weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status. J Neurooncol 2009;92:373-86.
15. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109.
16. Metellus P, Coulibaly B, Colin C, et al. Absence of IDH mutation identifies a novel radiologic and molecular subtype ofWHOgrade II gliomas with dismal prognosis. Acta Neuropathol 2010;120: 719-29.
17. Vanhamme L, van den Boogaart A, Van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson 1997;129:35-43.
18. Le Fur Y, Nicoli F, Guye M, et al. Grid-free interactive and automated data processing for MR chemical shift imaging data. MAGMA 2010;23:23-30.
19. Wetzel SG, Cha S, Johnson G, et al. Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. Radiology 2002;224:797-803.
20. Breiman L. Random forests. Machine Learning 2001;45:5-32.
21. Möller-Hartmann W, Herminghaus S, Krings T, et al. Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology 2002;44:371-81.
22. White ML, Zhang Y, Kirby P, et al. Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas? AJNR Am J Neuroradiol 2005;26:784-90.
23. Megyesi JF, Kachur E, Lee DH, et al. Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res 2004;10:4303-06.
24. Zlatescu MC, TehraniYazdi A, Sasaki H, et al. Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res 2001;61:6713-15.
25. Hilario A, Ramos A, Perez-Nuñez A, et al. The added value of apparent diffusion coefficient to cerebral blood volume in the preoperative grading of diffuse gliomas. AJNR Am J Neuroradiol 2012;33: 701-07.
26. Whitmore RG, Krejza J, Kapoor GS, et al. Prediction of oligodendroglial tumor subtype and grade using perfusion weighted magnetic resonance imaging. J Neurosurg 2007;107:600-09.
27. Spampinato MV, Smith JK, Kwock L, et al. Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors. AJR Am J Roentgenol 2007;188:204-12.
28. Xu M, See SJ, Ng WH, et al. Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors. Neurosurgery 2005;56:919 -26; discussion 919-26.
29. Chawla S, Wang S, Wolf RL, et al. Arterial spin-labeling and MR spectroscopy in the differentiation of gliomas. AJNR Am J Neuroradiol 2007;28:1683-89.
30. Galanaud D, Nicoli F, Chinot O, et al. Noninvasive diagnostic assessment of brain tumors using combined in vivo MR imaging and spectroscopy. Magn Reson Med 2006;55:1236-45.
31. Smith JK, Castillo M, Kwock L. MR spectroscopy of brain tumors. Magn Reson Imaging Clin N Am 2003;11:415-29, v-vi.
32. Gupta RK, Cloughesy TF, Sinha U, et al. Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma. J Neurooncol 2000;50:215-26.